- Infants and children who survive bleeding strokes may be prone to seizures and epilepsy within two years.
- Patients who had elevated pressure in the brain that required treatment were more likely to have later seizures or epilepsy.
Bleeding into brain tissue is a type of stroke called intracerebral hemorrhage (ICH). Each year, an estimated 6.4 newborns and children per every 100,000 in the United States suffer strokes. About half of the strokes are hemorrhagic, typically caused by rupturing of weakened or malformed blood vessels.
In the largest study of its kind, researchers tracked 73 subjects including 53 children, ranging in age from one month to 18 years, and 20 newborns, who experienced ICH between 2007 and 2012 at three hospitals.
Visible seizures occurring more than a week after the ICH were classified as remote symptomatic seizures. Such longer-term seizures suggest epilepsy might be developing, said Lauren A. Beslow, M.D., M.S.C.E., lead study author and now an instructor of pediatrics and neurology at Yale University in New Haven, Conn.
Among the study’s findings:
- About 60 percent of the newborns and 43 percent of the older children had visible seizures at the time of the stroke or within a week after.
- Of 32 patients who had continuous electroencephalographic monitoring, 28 percent had seizures that otherwise would have gone undetected. The researchers plan to explore whether these subtle seizures are a risk factor for more seizures, epilepsy or other problems over the long-term.
- About 13 percent of all study subjects developed epilepsy within two years.
- Patients who had elevated pressure in the brain that required medical or surgical treatment were more likely to have later seizures and epilepsy.
“Information on the risk for later seizures and epilepsy provides practitioners with concrete numbers that can be presented to families,” Beslow said. “While an estimate of 13 percent may seem low at two years, the rate of epilepsy might be greater at later time points.”
A key strength of the study is that data was collected in real time, rather than after the fact. But with just 73 patients and few that had remote seizures or developed epilepsy, the team could not explore all potential risk factors for the development of epilepsy.
Factors that make newborns vulnerable to ICH are not well understood, but include fetal distress, sepsis, blood conditions, exposure to blood thinners, and congenital heart disease. For older children, malformed blood vessels, blood disorders, or exposure to blood thinners can also play a role in developing ICH.
The research was led by Lori C. Jordan, M.D., Ph.D., at Vanderbilt University in Nashville, Tenn.; Rebecca N. Ichord, M.D., at The Children’s Hospital of Philadelphia; and Beslow who was a fellow and then an instructor at The Children’s Hospital of Philadelphia when the study was conducted. Patients were from those two institutions and Johns Hopkins University in Baltimore.
Other co-authors are Nicholas S. Abend, M.D.; Melissa C. Gindville, B.S., M.S.; Rachel A. Bastian, B.A.; Daniel J. Licht, M.D. and Sabrina E. Smith, M.D., Ph.D. Author disclosures are on the abstract.
The National Institutes of Health and the L. Morton Morley Funds of the Philadelphia Foundation funded this research.
Follow news from the American Stroke Association’s International Stroke Conference 2013 via Twitter @HeartNews; #ISC13.
Learn more from the American Stroke Association about stroke in children.
Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
Note: Actual presentation of this moderated poster is 4:25 p.m. HT, Thursday, Feb. 7, 2013.
All available downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link. Video clips with researchers/authors of studies will be added to the release links after embargo.